Total
0
Shares
Creso Pharma (ASX:CPH) could receive up to $17.4 million in extra funding
  • Creso Pharma (CPH) has introduced a remote working policy to curb the workplace impact of COVID-19
  • The majority of Creso's staff in Sydney and Switzerland are now working from home
  • Additionally, the company's Canadian Mernova Medical Facility has implemented a shift timetable and appointed a social distance coordinator to help manage everyone's workload
  • In the meantime, Creso is continuing to progress towards securing a European Union Good Manufacturing Practice (EU GMP) certification
  • This will allow Mernova to begin exporting its cannabis flower and oil into European markets
  • Creso is down slightly on the market this afternoon, trading for 5.9¢ per share

Creso Pharma (CPH) has introduced a remote working policy to curb the workplace impact of COVID-19.

“Creso Pharma is continuing to monitor the situation as it unfolds and is taking precautionary steps to prepare for the potential impacts a continued disturbance may have on supply chains and sales," CEO Miri Halperin Wernli said.

Saftey and cost-reduction methods

Under Creso's remote working policy, the majority of its staff in Sydney and Switzerland are now working from home. Travel and social distancing measures are been promoted by all staff.

Mernova

Mernova has begun operating three shifts a day with specific start and finish times to minimise contact between employees, while the facility is able to maintain production levels.

The company said a social distance coordinator has been appointed to enforce the recommendations for social distancing at all times.

The facility is also taking steps to manage less essential production tasks and is implementing all administration staff work from home.

Creso also said non-essential contractors and other third parties are not permitted on the site.

Rising demand for Mernova's products

Despite the challenging environment, Creso is working to maintain its business presence.

The company is also continuing to progress towards securing European Union Good Manufacturing Practice (EU GMP) certification. This EU GMP will allow Mernova to begin exporting its cannabis flower and oil into European markets.

The company expects to have further positive updates on this certification in the coming months.

"The COVID-19 pandemic will enhance our focus on continued operational improvements and efficiencies," Miri said.

"Creso Pharma’s lean organisational structure means that our operations are not affected by international travel bans. We believe we all should do our part to slow the spread of the virus and we hope to see improvements in the global situation in the weeks ahead," she added.

Creso is down slightly on the market this afternoon, trading for 5.9¢ per share.


Subscribe


CPH by the numbers
More From The Market Herald
OBJ (ASX:OBJ) - CEO, Paul Peros - The Market Herald

" OBJ (ASX:OBJ) to raise $4.5M for product development and licencing

Innovative wellness company OBJ (OBJ) is aiming to raise $4.5 million through an entitlement offer and placement for licencing, development and general workin…
Creso Pharma (ASX:CPH) - CEO & Co Founder, Dr Miri Halperin Wernli (left) and Chairman, Boaz Wachtel (right) - The Market Herald

" Creso Pharma (ASX:CPH) subsidiary receives follow-up order from Univo Pharmaceuticals

Creso Pharma’s (CPH) subsidiary, Mernova Medicinal, has received a US$625,690 (roughly A$901,830) purchase order from Univo Pharmaceuticals.
Holista Colltech (ASX:HCT) - Managing Director, Dr Rajen Manicka - The Market Herald

" Holista CollTech (ASX:HCT) misses the mark for hand sanitiser product

Holista CollTech (HCT) has downgraded its $3.8 million in expected sales from its hand sanitiser product, Natshield, due to COVID-19 and race riots.
Cellmid (ASX:CDY) - CEO, Maria Halasz (right) - The Market Herald

" Cellmid (ASX:CDY) signs distribution agreement for SARS-CoV-2 and ELISA’s

Cellmid (CDY) has signed a distribution agreement with Immunodiagnostics (IMD) for Enzyme Linked Immunosorbent Assays (ELISA’s) and SARS-CoV-2 tests in Australia and New